NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT01933711,Rituximab Maintenance Therapy in Aggressive CD20 (Cluster of Differentiation Antigen 20) Positive Lymphoma and Mantle Cell Lymphoma,https://clinicaltrials.gov/study/NCT01933711,,UNKNOWN,Clinical and pharmacokinetic data suggest that the effect of rituximab could be improved by prolonged exposure to the drug. To test for this hypothesis we performed a prospective randomized trial of rituximab maintenance therapy versus observation in patients (pts) with aggressive CD20+ B-cell lymphoma and mantle cell lymphoma.,NO,"CD20+ Aggressive Lymphoma, Mantle Cell Lymphoma",DRUG: rituximab,"Progression free survival, Primary endpoint of the study was progression free survival (PFS), 24 months after randomization","time to progression (TTP), 24 months after randomization|overall survival (OS), 24 months after randomization|response to treatment, 24 months after randomization",,University Hospital Heidelberg,,ALL,"ADULT, OLDER_ADULT",PHASE3,328,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,HD2002,2002-07,2016-12,2018-12,2013-09-02,,2016-05-13,"University of Heidelberg Hospital, Heidelberg, Baden-Württemberg, 69120, Germany|University of Mannheim Hospital, Mannheim, Baden-Württemberg, 68167, Germany|University of Bonn Hospital, Bonn, Nordhein-Westfalen, 53127, Germany",
